Late-breaking abstracts from the annual American Society of Hematology meeting are early this year, coming right before Thanksgiving instead of the previously planned drop on Dec. 1. Big pharma companies are seeking to expand the …
Otsuka preps for July decision on centanafadine for ADHD
The FDA has started a priority review of Otsuka’s triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.


